In line with these mouse studies, analysis of human breast cancer genomics using TCGA databases showed that copy number gains of WIP1 or MIR21 are significantly correlated with poor clinical outcomes in patients with HER2+ breast cancer, but not in patients with luminal A, luminal B or basal-like breast cancer (Fig. 2b). The gene discussed is ERBB2; the disease is breast cancer.